Sponsored by ShareVault, Pullan Consulting, Defined Health and BIO
In this live web panel, the panelists will discuss the role of non-immuno-oncology treatments for cancer in a world where immuno-oncology is playing a greater role. Biotech licensing and pharmaceutical business development consultant Linda Pullan will be joined by four panelists who are business development experts from global pharmaceutical companies, a leading academic cancer center, and a top business development consulting firm.
The clinical success of checkpoint inhibitors has made Immuno-Oncology an amazingly “hot” area for pharmaceutical and biotech deal making. With checkpoint antibodies seen as backbones for combination therapy in cancer, many in Oncology are asking:
- What is the role of non-IO in an IO world and can you partner a non-IO opportunity?
- Is there still room for new anticancer agents that are not working in IO models?
- Are drug candidates evaluated with the assumption that everything will eventually be used in combination with IO agents? Or are there indications or mechanisms for which IO will never be important? Should I pursue combinations with IO?
- What kinds of mechanisms are attractive in non-IO? What data and models will big pharma want to see? Do I need to run experiments with their molecule? Are there certain tumor types that are particularly attractive?
- Is it too late to try to compete in the crowded space of combination with PD1 antibodies? What other IO agents are likely to backbones of oncology franchises?
- What will make my non-IO drug candidate compelling for partners and investors?
We will ask these experts from industry and academia the questions and answer your questions as well.
Moderator: Linda Pullan, PhD | Pullan Consulting
- Jeff Bockman, PhD | Defined Health
- Peter Sandor, MD, MBA | Astellas Pharma
- Axel Hoos, MD, PhD | GlaxoSmithKline
- Eric Haura, MD | H. Lee Moffitt Cancer Center
To join this lively Q&A, register here: http://bit.ly/2iA43C1